A pharmaceutical company running a multi-site clinical trial—with investigators in Boston, London and Munich—faces a compliance question before its first patient is enrolled: which privacy framework governs the data? The answer is both. HIPAA applies to the US sites. GDPR governs every EU data subject, regardless of where the data is processed. As AI-powered analytics and cross-border research pipelines become standard in healthcare and life sciences, the HIPAA vs GDPR comparison has moved from a compliance abstraction to a daily operational challenge for data teams, legal counsel and compliance officers.
The practical differences between the two frameworks go deeper than geography. They diverge on who is covered, how de-identification works, what rights individuals hold and what it costs to get it wrong. This guide breaks down the key distinctions so your compliance team, data engineers and legal counsel can act on them.
HIPAA overview: who it covers and what it protects
The Health Insurance Portability and Accountability Act was enacted in 1996 and updated through the HITECH Act (Health Information Technology for Economic and Clinical Health Act) in 2009. The Privacy Rule, which governs PHI, establishes how protected health information can be used, disclosed and de-identified.
Who HIPAA applies to
HIPAA applies to two categories of organizations:
- Covered entities: health plans, healthcare clearinghouses and healthcare providers that transmit health data electronically
- Business associates: vendors and service providers that create, receive, maintain or transmit PHI on behalf of a covered entity
Critically, HIPAA does not apply to all organizations that touch health data. A fitness app that collects health metrics, for example, is not a covered entity unless it is working directly with a healthcare provider or health plan in a covered capacity.
What counts as PHI
PHI is individually identifiable health information that relates to a person's past, present, or future physical or mental health condition, the provision of healthcare or payment for healthcare services. The HIPAA Privacy Rule identifies 18 specific categories of identifiers that, when present alongside health data, make that information PHI. These include names, dates (other than year), geographic data below state level, phone numbers, email addresses, Social Security numbers and biometric identifiers.
HIPAA's two de-identification methods
HIPAA recognizes two legally valid methods for de-identifying PHI so it falls outside the Privacy Rule's protections:
- Safe Harbor method: Remove all 18 identifier categories and have no actual knowledge that the remaining data can identify an individual.
- Expert Determination method: A qualified statistician or other expert applies generally accepted statistical and scientific principles to certify that the risk of identifying an individual is very small.
Both methods, when properly applied, produce data that is no longer considered PHI under HIPAA. That data can then be used for research, analytics and AI training without the Privacy Rule's restrictions.
GDPR overview: scope, health data and anonymization
The General Data Protection Regulation came into force in May 2018 and applies across all 27 EU member states. It is arguably the broadest privacy law in the world in terms of reach: it applies to any organization that processes personal data of people in the EU, regardless of where that organization is located.
Health data as a "special category"
Under GDPR, health data is classified as a special category of personal data under Article 9, which prohibits processing unless one of a limited set of legal bases applies. The most relevant for regulated organizations are:
- Explicit consent from the data subject
- Substantial public interest, as defined by member state law
- Preventive or occupational medicine, medical diagnosis or the provision of health care
- Reasons of public health, such as protecting against serious cross-border threats
- Scientific or historical research with appropriate safeguards (Article 9(2)(j))
Each basis has specific conditions attached. For AI training and analytics, most organizations rely on explicit consent or the scientific research basis—and must document which applies before processing begins.
PHI vs personal data: how each framework defines health information
The two frameworks use different definitions, and the gap matters operationally. Under HIPAA, PHI is health data linked to any of the 18 specific identifier types. Remove those identifiers and the data is no longer PHI under Safe Harbor. Under GDPR, "personal data" is any information relating to an identified or identifiable natural person—a much broader definition. Health data is a subcategory that triggers Article 9 protections the moment it can be linked to a living individual, even indirectly.
This means data that is de-identified under HIPAA may still be personal data under GDPR if indirect identification remains possible. A dataset with zip codes, dates of birth and diagnosis codes, for example, might clear HIPAA's Safe Harbor threshold while still being identifiable under GDPR's standard.
How GDPR defines anonymization
Under GDPR, truly anonymized data—data altered in such a way that the individual is not, or is no longer, identifiable—falls entirely outside the regulation. Recital 26 of GDPR states explicitly that the regulation does not apply to anonymous information. This is a significant incentive for de-identification: once data crosses GDPR's anonymization threshold, it can be used freely for analytics, AI training and research.
However, the bar is high. Pseudonymized data—where a key or lookup table could re-identify individuals—is still considered personal data under GDPR and subject to its full requirements. The three concepts—de-identification, anonymization and pseudonymization—carry distinct legal weight under GDPR, and confusing them is one of the most common compliance mistakes global organizations make. Achieving true GDPR anonymization requires that re-identification is not reasonably possible, even by the original controller.
HIPAA's Safe Harbor method does not meet GDPR's anonymization standard. Removing the 18 identifiers reduces re-identification risk to a defined threshold—it does not guarantee that re-identification is impossible. Organizations processing data from both US patients and EU data subjects cannot apply a single de-identification approach and consider both frameworks satisfied.
HIPAA vs GDPR: side-by-side comparison
A jurisdictional nuance worth noting: HIPAA's jurisdiction is entity-based, meaning it attaches to covered entities and business associates regardless of where they are located. GDPR's jurisdiction is data-subject-based, meaning it follows the individual whose data is being processed. These two approaches can create overlapping obligations for organizations with international operations in healthcare.
The table below captures the most operationally significant differences between the two frameworks.
| Dimension |
HIPAA |
GDPR |
| Geographic scope |
United States |
Any organization processing EU residents' data, globally |
| Who it applies to |
Covered entities and business associates |
Any data controller or processor of EU residents' personal data |
| Health data definition |
PHI: individually identifiable health data linked to 18 identifier types |
Personal data (broad): any info relating to an identifiable person; health data is special category |
| De-identification standard |
Safe Harbor (18 identifiers removed) or Expert Determination |
Full anonymization required (Recital 26); pseudonymized data remains regulated |
| Maximum penalties |
Up to ~$1.9M per violation category per year (2023 adjusted) |
Up to €20M or 4% of global annual turnover, whichever is higher |
| Individual rights |
Access, amendment, accounting of disclosures |
Access, rectification, erasure, portability, restriction, right to object |
| Cross-border data transfer |
No equivalent restriction within the US |
Restricted—requires SCCs, adequacy decisions or other approved mechanisms |
| Consent requirement |
Not always required for treatment, payment and operations |
Explicit consent is one of six legal bases; required for special category data unless another basis applies |
| AI and analytics use |
De-identified data can be used freely; identified data requires authorization |
Anonymized data can be used freely; all other processing requires a documented legal basis |
Key practical differences that trip up global organizations
Understanding the regulatory text is one thing. Operating under both frameworks simultaneously is another. Here are the specific divergences that most often create compliance problems in practice.
HIPAA's Safe Harbor doesn't satisfy GDPR
This is the most common mistake global organizations make. A dataset de-identified under HIPAA's Safe Harbor—all 18 identifiers removed—is still considered personal data under GDPR if re-identification remains reasonably possible. GDPR requires that data be genuinely anonymous, not merely de-identified to a defined threshold. Organizations that process data from both US patients and EU data subjects cannot apply a single de-identification approach and consider both frameworks satisfied.
Pseudonymization means different things under each framework
Under GDPR, pseudonymization is explicitly recognized as a security measure that reduces risk but does not remove data from the regulation's scope—pseudonymized data is still personal data under GDPR. Under HIPAA, pseudonymization is not a formally defined de-identification method, and data retaining indirect identifiers (such as a patient ID linked to a lookup table) would not meet the Safe Harbor standard either. Both frameworks reference pseudonymization, but with different legal implications.
Data subject rights create operational complexity
GDPR grants EU data subjects significantly broader rights than HIPAA grants US patients. The GDPR right to be forgotten—the right to erasure—requires organizations to delete personal data upon request unless a legal basis for retention exists. HIPAA grants patients the right to access and amend their records but includes no comparable erasure right. For a global research organization storing health data in a combined environment, this creates the challenge of locating and deleting EU subject data without disrupting US patient records.
Cross-border data transfers require explicit mechanisms under GDPR
Transferring personal data from the EU to the United States requires a legal transfer mechanism under GDPR—such as Standard Contractual Clauses (SCCs) or the EU-US Data Privacy Framework. HIPAA has no equivalent cross-border restriction within a US context. For pharma companies and contract research organizations (CROs) conducting multi-national clinical trials, patient data flowing between EU sites and US analytical teams must be governed by both a HIPAA-compliant data use agreement and a valid GDPR transfer mechanism.
Penalty structures differ significantly
HIPAA penalties are tiered by culpability—ranging from $100 to $50,000 per violation—with annual caps per violation category. Following the 2023 inflation adjustments, the maximum annual penalty for the highest culpability tier is approximately $1.9 million per violation category. GDPR penalties are far larger in absolute terms—up to €20 million or 4 percent of global annual turnover, whichever is higher—and apply to any organization worldwide that processes EU residents' data improperly.
How to handle both frameworks simultaneously
Organizations that operate under both HIPAA and GDPR need a data privacy approach that satisfies both standards. The most reliable way to achieve this is to meet the stricter of the two requirements—which, in most cases, means GDPR's full anonymization standard.
Start with GDPR's anonymization threshold
If your de-identification approach meets GDPR's anonymization standard—meaning re-identification is not reasonably possible, even using auxiliary data or adversarial methods—then your data is also effectively de-identified under HIPAA. The reverse is not true. Building your de-identification pipeline to GDPR's standard gives you coverage under both frameworks by design.
Document your legal basis for processing under GDPR
For any health data processing that has not been fully anonymized, you need a documented legal basis under GDPR Article 9. For research, this is typically Article 9(2)(j) (scientific research with appropriate safeguards). For employment-related health data, it may be Article 9(2)(b). Your legal basis must be documented and, where required, communicated to data subjects.
Use in-VPC deployment for data sovereignty
Both HIPAA and GDPR impose requirements that affect where and how data is processed. HIPAA's Security Rule requires administrative, physical and technical safeguards over PHI. GDPR requires that data transferred outside the EU maintains equivalent protections. Deploying de-identification infrastructure within your own virtual private cloud (VPC)—rather than routing data through a third-party cloud API—means your PHI and special category data never leave your controlled environment. This satisfies both HIPAA's security requirements and GDPR's data sovereignty principles. Limina deploys in-VPC or on-premises specifically for organizations handling sensitive health data under multiple regulatory frameworks simultaneously.
Ready to de-identify health data across HIPAA and GDPR?
Limina's de-identification platform is purpose-built for organizations operating under multiple privacy frameworks simultaneously. With in-VPC deployment, 99.5 percent accuracy on real healthcare data and support for 50+ entity types across 52 languages, Limina helps compliance, legal and data teams meet both HIPAA and GDPR requirements without compromising data utility.
Get a demo to see how Limina handles dual-framework compliance in your environment.
Read our complete HIPAA expert determination guide for a deeper dive into HIPAA's two de-identification methods.
